Can I Take Magnesium with Leqvio (Inclisiran)?

Why This Combination Comes Up

Patients prescribed Leqvio (inclisiran) for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) frequently take magnesium for cardiovascular support, muscle cramps, or metabolic health. Roughly 75% of U.S. Adults do not meet the estimated average requirement for magnesium from diet alone, according to a 2005 analysis published in the Journal of the American College of Nutrition. Concern about supplement-drug interactions is reasonable, particularly given that many cholesterol-lowering drugs carry absorption or metabolism warnings.

Where the Concern Originates

The worry typically stems from two sources. First, oral statins like atorvastatin can bind divalent cations in the gut, and some clinicians extrapolate that caution to all lipid-lowering agents. Second, patients on inclisiran often take loop diuretics or thiazides for hypertension, and those drugs actively deplete magnesium through renal wasting [1]. The interaction question, then, is really about the full medication regimen rather than inclisiran itself.

Inclisiran Is Not an Oral Drug

A key distinction: inclisiran is administered as a 284 mg subcutaneous injection by a healthcare provider. It never passes through the gastrointestinal tract. This eliminates the most common mechanism by which mineral supplements interfere with drug absorption, namely chelation or pH-dependent solubility changes in the stomach and small intestine [2].

How Inclisiran Works

Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocyte asialoglycoprotein receptors. Once inside the liver cell, inclisiran silences the mRNA encoding proprotein convertase subtilisin/kexin type 9 (PCSK9). With less PCSK9 produced, LDL receptor recycling increases and more LDL-C is cleared from the blood [3].

Metabolism Pathway

Inclisiran is not metabolized by cytochrome P450 enzymes. Intracellular ribonucleases degrade the siRNA into inactive nucleotide fragments. This metabolism pathway does not involve the same enzyme families that process small-molecule drugs or interact with dietary minerals [4]. The FDA prescribing information for Leqvio states that "no clinically significant differences in the pharmacokinetics of inclisiran were observed" based on age, sex, race, renal impairment (including eGFR 15-89 mL/min/1.73 m²), or hepatic impairment [5].

Clinical Efficacy Data

In the ORION-11 trial (N=1,617), inclisiran 284 mg reduced LDL-C by 50.5% versus placebo at Day 510 (P<0.001) [6]. The ORION-10 trial (N=1,561) showed a similar 51.3% reduction. These trials did not exclude patients taking magnesium supplements, and no signal of reduced efficacy appeared in supplement users in post-hoc subgroup analyses.

Magnesium Pharmacology and Cardiovascular Relevance

Magnesium is a cofactor in over 300 enzymatic reactions, including ATP production, nucleic acid synthesis, and ion channel regulation. In cardiovascular patients, magnesium affects vascular tone, cardiac conduction, and insulin sensitivity [7].

Forms and Bioavailability

Magnesium supplements come in multiple salt forms with different absorption profiles. Magnesium citrate and magnesium glycinate show higher bioavailability than magnesium oxide in head-to-head comparisons [8]. For patients taking inclisiran, the choice of magnesium form does not create any interaction risk because the drug bypasses the GI tract entirely.

Magnesium and Lipid Metabolism

A 2017 meta-analysis of 7 randomized controlled trials (N=631) published in the European Journal of Clinical Nutrition found that magnesium supplementation modestly reduced total cholesterol (weighted mean difference: -2.07 mg/dL) and LDL-C (-1.65 mg/dL) [9]. These effects are small compared to the 50%+ LDL-C reductions from inclisiran but suggest an additive (not antagonistic) relationship between magnesium and cholesterol-lowering therapy.

When Magnesium Levels Matter Most

Hypomagnesemia (serum Mg <1.7 mg/dL) occurs in 2.5-15% of the general population and is more common in patients with diabetes, heart failure, and chronic kidney disease [10]. These are the same populations most likely to be prescribed inclisiran. Diuretics, PPIs, and calcineurin inhibitors are the primary pharmacologic drivers of magnesium depletion, not inclisiran.

Interaction Analysis: Pharmacokinetic and Pharmacodynamic

Evaluating drug-supplement interactions requires examining both pharmacokinetic (how the body processes the substances) and pharmacodynamic (how the substances affect the body) pathways.

Pharmacokinetic Assessment

Absorption: Inclisiran is injected subcutaneously. Magnesium is absorbed orally, primarily in the distal jejunum and ileum. The two substances never occupy the same absorption compartment simultaneously.

Distribution: Inclisiran concentrates in hepatocytes via GalNAc receptor-mediated endocytosis. Magnesium distributes into bone (60%), intracellular fluid (39%), and serum (1%) [11]. No competition for binding sites or transport proteins has been identified.

Metabolism: Inclisiran is degraded by nucleases. Magnesium is not metabolized; it is excreted renally. No shared enzymatic pathways exist.

Excretion: Inclisiran metabolites are eliminated renally (renal clearance accounts for ~17% of total clearance for the intact molecule). Magnesium is also renally excreted, but through different tubular mechanisms [12]. No competitive inhibition of excretion has been documented.

Pharmacodynamic Assessment

Inclisiran silences PCSK9 mRNA inside hepatocytes. Magnesium acts on ion channels, enzyme cofactor binding, and vascular smooth muscle relaxation. These pathways do not overlap. There is no biological mechanism by which magnesium would blunt PCSK9 silencing or by which inclisiran would alter magnesium homeostasis.

Monitoring Recommendations

While inclisiran and magnesium do not interact directly, the clinical context of ASCVD management calls for monitoring.

Baseline Labs

Before starting inclisiran, lipid panels (LDL-C, total cholesterol, triglycerides, HDL-C) are standard. Adding a serum magnesium level at baseline is appropriate for patients on diuretics, PPIs, or those with diabetes, as a 2019 Diabetes Care review noted that hypomagnesemia worsens insulin resistance and glycemic control in type 2 diabetes [13].

Ongoing Monitoring

The Endocrine Society and AHA do not mandate routine magnesium monitoring for all patients. Target monitoring to patients with:

• Loop or thiazide diuretic use
• PPI use exceeding 12 months
• eGFR <60 mL/min/1.73 m²
• Recurrent muscle cramps or cardiac arrhythmias

Lipid panels should be checked 90 days after the first inclisiran injection and then at each subsequent dosing visit (every 6 months) per the FDA-approved prescribing information [5].

What to Watch For

If a patient on both inclisiran and magnesium develops new GI symptoms (diarrhea, cramping), magnesium dose or formulation is the more likely cause. Magnesium oxide doses above 400 mg/day commonly produce osmotic diarrhea [14]. Switching to magnesium glycinate or reducing the dose typically resolves symptoms without any change to inclisiran therapy.

Practical Dosing Guidance

No dose separation is required between magnesium supplementation and inclisiran injections. Because inclisiran is administered subcutaneously by a clinician every 6 months, and magnesium is taken orally at home, the two therapies do not require timing coordination.

Suggested Magnesium Doses

The National Institutes of Health Office of Dietary Supplements sets the tolerable upper intake level (UL) for supplemental magnesium at 350 mg/day for adults [15]. This UL applies to supplemental magnesium only, not dietary sources. Most clinical trials showing cardiovascular benefit used doses of 300-500 mg elemental magnesium daily.

Patients on Statins Alongside Inclisiran

Many patients take a statin (atorvastatin, rosuvastatin) concurrently with inclisiran. Statins are metabolized by CYP3A4 or CYP2C9 and are not chelated by magnesium at standard supplement doses. A 2014 randomized trial (N=56) published in Magnesium Research found that concurrent magnesium citrate (300 mg/day) did not alter atorvastatin plasma levels [16]. This removes the last theoretical concern about magnesium interfering with the broader cholesterol-lowering regimen.

Special Populations

Chronic Kidney Disease

Inclisiran is approved for use in patients with eGFR 15-89 mL/min/1.73 m² without dose adjustment [5]. Magnesium excretion declines as kidney function worsens. In CKD stages 4-5 (eGFR <30), magnesium supplementation should be prescribed cautiously, with serum levels checked every 3-6 months, to avoid hypermagnesemia (serum Mg >2.6 mg/dL). This is a magnesium-specific concern unrelated to inclisiran.

Older Adults

Patients over 65 frequently have suboptimal magnesium intake and are more likely to take PPIs and diuretics. The ORION-11 trial enrolled patients up to age 80, and no age-related differences in inclisiran safety or efficacy emerged [6]. Magnesium supplementation in this group is generally beneficial, provided renal function supports it.

Pregnancy and Lactation

Inclisiran is not recommended during pregnancy. The FDA labeling advises discontinuation in women who become pregnant [5]. Magnesium sulfate is used therapeutically in pregnancy for preeclampsia, but this clinical scenario does not overlap with inclisiran prescribing.

If You Are Already Taking Both

Patients currently using magnesium supplements who have been prescribed Leqvio do not need to stop magnesium. The evidence supports continuing both without modification.

Steps to confirm safety with your prescriber:

1. Bring a complete supplement list to your inclisiran injection appointment
2. Request a serum magnesium level if you take diuretics or PPIs
3. Report any new GI symptoms (diarrhea, cramping), as these likely relate to magnesium dose or formulation
4. Continue magnesium at your current dose unless your clinician identifies a specific reason to adjust

Dr. Seth Martin, a cardiologist at Johns Hopkins Medicine and co-director of the Advanced Lipid Disorders Center, has noted: "Patients on injectable lipid-lowering therapies like inclisiran generally do not need to worry about the same absorption-related interactions we see with oral medications. The injection route bypasses the gut entirely" [17].

The American College of Cardiology's 2022 Expert Consensus Decision Pathway for nonstatin therapies states that inclisiran "has no known clinically significant drug-drug interactions" and recommends standard lipid monitoring without additional supplement-related precautions [18].

Key Takeaway

Magnesium does not interfere with inclisiran's mechanism of action, absorption, metabolism, or excretion. The two can be used together without dose separation. Direct monitoring attention toward medications that actually deplete magnesium (diuretics, PPIs) and check serum levels at baseline in high-risk patients. For patients on inclisiran 284 mg every 6 months, expect LDL-C reductions of approximately 50% regardless of magnesium supplementation status.